Is open innovation the way forward for big pharma?

Nature Reviews Drug Discovery

Volumn 9, Issue 2, 2010, Pages 87-88

  Hunter, Jackie ^a   Stephens, Susie ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Johnson and Johnson Pharmaceutical Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COOPERATION; DRUG INDUSTRY; NOTE; ONLINE SYSTEM; PATENT; PRIORITY JOURNAL; RESEARCH; SUSTAINABLE DEVELOPMENT;

EID: 75949093281     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3099     Document Type: Note

References (7)

1. Chesborough, H. W. Open Innovation: the New Imperative for Creating and Profiting from Technology 1-272 (Harvard Business School, Boston, Masschusetts, 2003).
2. Tapscott, D. & Williams, A. D. Wikinomics: How Mass Collaboration Changes Everything 1-320 (Portfolio, New York, 2006).
3. Munos, B. Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov. 5, 723-729 (2006).
4. Huston, L. & Sakkab, N. Connect and Develop: Inside Procter & Gamble's new model for innovation. Harv. Bus. Rev. 84, 58-66 (2006).
5. Barnes, M. R. et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nature Rev. Drug Discov. 8, 701-708 (2009).
6. Hughes, B. Harnessing open innovation. Nature Rev. Drug Discov. 8, 344-345 (2009).
7. Alexy, O. et al. Does IP strategy have to cripple open innovation?' MIT Sloane Management Rev. 51, 73-77 (2009).